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The largest studies report a 1.85-34-fold increase in the risk of SSM compared with the general population, with a median time from AHCT to diagnosis of 3.3-6.8 years. [2] [3] [4] In a study of 19 229 patients, treated either by allogeneic HCT (97.2%) or syngeneic HCT (2.8%), Curtis et al. 5 showed a relative risk of SSM of 2.7, which rose to 8.3 for patients surviving more than 10 years.
Although lung cancer is common in the general population, it is rarely reported as an SSM. Non-significant trends have been found in AHCT cohorts. The most frequent pathological subtypes are adenocarcinoma and epidermoid cancer. To date, no cases of pneumoblastoma (PB) have been reported. PB is a rare type of lung cancer occurring in young adults. Histologically, it resembles a normal fetal lung.
We report here what, to our knowledge, is the first case of PB occurring as an SSM after AHCT.
A 40-year-old man underwent AHCT as consolidation treatment for chronic myeloid leukaemia in chronic phase, before the era of imatinib (date of graft ¼ September 2000). He smoked 26 packets/year but stopped in 1993. First-line treatment before AHCT was hydroxycarbamide for 3 months.
The conditioning regimen was BU 16 mg/kg and CY 150 mg/kg (no irradiation). GVHD prophylaxis comprised CYA 3 mg/kg, and MTX 15 mg/m 2 on day 1 and 10 mg/m 2 on days 2 and 6. There were no early complications after AHCT. However, four chronic complications occurred during the 8-year 
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Numerous metastatic mediastinal lymph nodes were present. The patient was staged as pT4N2M0. (Figure 2) One month after the surgery, pleural effusion owing to pleural metastasis occurred, and led to electrolyte and fluid disturbances with hypercalcaemia. The patient was given supportive care, but died 2 months after surgery, before any adjuvant chemotherapy could be started.
To our knowledge, this report is the first description of PB as a long-term complication of AHCT. It may have resulted from immunosuppressive therapy for c-GVHD, smoking or chemotherapy. Surgical resection is the gold standard treatment. Radiotherapy is used only as palliative treatment to relieve dyspnoea when other treatments fail. The prognosis is poor: 5-year survival is estimated at 16% (8% for long-term survivors). Metastases occur mainly in the liver, brain and bones. 6 In conclusion, the cumulative incidence of SSM continues to increase, even in large studies with a follow-up as long as 20 years. At this time, tumours such as the PB described here are observed occasionally. It seems to us mandatory to register all acute and chronic late complications in an AHCT database. With sufficient data, we believe guidelines could be proposed for screening strategies designed to allow earlier diagnosis and thereby increasing the number of patients cured.
